The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Abstract
Purpose: Targeted therapy with the humanized monoclonal antibody trastuzumab has become a mainstay for human epidermal growth factor receptor 2 (HER2) –positive breast cancer (BC). The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here. The impact of the mechanisms of action on clinical benefit also is discussed. Methods: An extensive literature review of trastuzumab and proposed mechanisms of action was performed. Results: At least five potential extracellular and intracellular antitumor mechanisms of trastuzumab have been identified in the preclinical setting. These include activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signaling, reduction of angiogenesis, and decreased DNA repair. These effects lead to tumor cell stasis and/or death. Clinical benefit from trastuzumab-based therapy in both early and advanced BC has been demonstrated. The benefit of trastuzumab use beyond progression has also been shown, which indicates the need for continuous suppression of the HER2 pathway. Targeting both HER2, with various approaches, and other pathways may enhance the clinical benefit observed with trastuzumab and overcome potential resistance. Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a HER1/HER2 tyrosine kinase inhibitor), bevacizumab (an antiangiogenic agent), tanespimycin (a heat shock protein inhibitor), antiestrogen therapies, and an antibody-drug conjugate (trastuzumab-DM1). Conclusion: Trastuzumab is the foundation of care for patients with HER2-positive BC. Emerging data from studies of other targeted agents may provide alternative treatment combinations to maximize the clinical benefit from trastuzumab and prevent or delay resistance. The continued development of trastuzumab highlights promising treatment approaches for the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“3 months) and ORR (50% v 32%).(18) This study resulted in approval of trastuzumab with paclitaxel for the first-line treatment of HER2-overexpressing MBC on the basis of a 62% reduction in the risk of disease progression (hazard ratio, 0.”
BackgroundJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“treated with a modified 4D5 antibody incapable of activating Fc receptors on effector cells.(33) Laboratory studies also have shown”
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“01).(91) However, another study found that PFS was not significantly different for patients who had tumors with low or normal PTEN levels and who received a variety of trastuzumab-based therapies (P .”
ResultBerns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 2×
“Prospective studies are needed to clarify the potential role of polymorphisms in predicting response or resistance to trastuzumab.(40,41)”
BackgroundMolina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 523
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
HER-2 gene amplification can be acquired as breast cancer progresses
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Pietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Perez, E. A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202132 · Cited by 386
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999) · PubMed · Cited by 353
Xu, W., Mimnaugh, E., Rosser, M. F. N., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006864200 · Cited by 353
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350
Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298
Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 286
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Self-citationXia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
Self-citationHarris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231
Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-22-cor1 · Cited by 230
Hancock, M. C., Langton-Webster, B. C., Chan, T., Toy, P., Monahan, J., Mischak, R. P., & Shawver, L. K. (1991) · PubMed · Cited by 225
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kauffman, P. A., & Wolmark, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.512 · Cited by 218
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213
Lu, Y., Zi, X., & Pollak, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 208
Lu, C.-H., Wyszomierski, S. L., Tseng, L.-M., Sun, M.-H., Lan, K.-H., Neal, C. L., Mills, G. B., Hortobagyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 200
Asanuma, H., Torigoe, T., Kamiguchi, K., Hirohashi, Y., Ohmura, T., Hirata, K., Sato, M., & Sato, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0491 · Cited by 195
Le, X., Claret, F.-X., Lammayot, A., Tian, L., Deshpande, D. M., LaPushin, R., Tari, A. M., & Bast, R. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300848200 · Cited by 178
Trastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram, M. D., Lopez, A. M., Konecny, G., & Slamon, D. (2000) · PubMed · Cited by 174
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.
Dowsett, M. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080191 · Cited by 171
Le, X., Pruefer, F., & Bast, R. C. (2004) · Cell Cycle · doi:10.4161/cc.4.1.1360 · Cited by 170
Xia, W., Chen, J.-S., Zhou, X., Sun, P.-R., Lee, D.-F., Liao, Y., Zhou, B. P., & Hung, M.-C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0527 · Cited by 166
Xia, W., Bisi, J., Strum, J. C., Liu, L.-H., Carrick, K., Graham, K. M., Treece, A. L., Hardwicke, M. A., Dush, M. K., Liao, Q., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2000 · Cited by 165
Self-citationFujita, T., Doihara, H., Kawasaki, K., Takabatake, D., Takahashi, H., Washio, K., Tsukuda, K., Ogasawara, Y., & Shimizu, N. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602926 · Cited by 161
Sabbatini, P., & McCormick, F. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24263 · Cited by 159
Bacus, S. S., Altomare, D. A., Lyass, L., Chin, D. M., Farrell, M. P., Gurova, K. V., Gudkov, A. V., & Testa, J. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205438 · Cited by 157
O’Shaughnessy, J., Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Sledge, G. W., Baselga, J. M., Koehler, M. T., Laabs, S., Florance, A. M., & Roychowdhury, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1015 · Cited by 154
Self-citationModulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling
Lane, H. A., Motoyama, A. B., Beuvink, I., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s21 · Cited by 148
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase
Hellyer, N. J., Cheng, K., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3330757 · Cited by 144
Fornier, M. N., Seidman, A. D., Schwartz, M. K., Ghani, F., Thiel, R. P., Norton, L., & Hudis, C. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi059 · Cited by 126
Unraveling the Biologic and Clinical Complexities of HER2
Park, J. W., Neve, R. M., Szöllõsi, J., & Benz, C. C. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.047 · Cited by 123
Storniolo, A. M., Pegram, M. D., Overmoyer, B. A., Silverman, P., Peacock, N. W., Jones, S. F., Loftiss, J., Arya, N., Koch, K. M., Paul, E. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5202 · Cited by 117
Neve, R. M., Holbro, T., & Hynes, N. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205555 · Cited by 114
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Repka, T. L., Chiorean, E. G., Gay, J., Herwig, K. E., Kohl, V., Yee, D., & Miller, J. S. (2003) · PubMed · Cited by 102
Mimura, K., Kono, K., Hanawa, M., Kanzaki, M., Nakao, A., Ooi, A., & Fujii, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2476 · Cited by 98
Camirand, A., Lu, Y., & Pollak, M. (2002) · PubMed · Cited by 98
Merlin, J., Barberi‐Heyob, M., & Bachmann-Moisson, N. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf263 · Cited by 83
von Minckwitz, G., Zielinski, C., Maarteense, E., Vogel, P., Schmidt, M., Eidtmann, H., Čufer, T., de Jongh, F. E., Kaufmann, M., & Loibl, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1025 · Cited by 76
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)
Argiris, A. E., Wang, C.-X., Whalen, S. G., & DiGiovanna, M. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1060-02 · Cited by 73
Le, X., Lammayot, A., Gold, D. L., Lu, Y., Mao, W., Chang, T., Patel, A. M., Mills, G. B., & Bast, R. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403080200 · Cited by 71
Johnston, S. R. D., Pegram, M. D., Press, M. F., Pippen, J., Pivot, X. B., Gómez, H., Florance, A. M., O’Rourke, L., & Maltzman, J. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-46 · Cited by 66
Menéndez, J. A., Mehmi, I., & Lupu, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3489 · Cited by 65
Söderlund, K., Pérez‐Tenorio, G., & Stål, O. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.1.25 · Cited by 50
Beeram, M., Burris, H. A., Modi, S., Birkner, M., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., & Krop, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1028 · Cited by 48
Fujita, T., Doihara, H., Washio, K., Kawasaki, K., Takabatake, D., Takahashi, H., Tsukuda, K., Ogasawara, Y., & Shimizu, N. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000198910.90819.06 · Cited by 40
Heregulin-dependent translocation and hyperphosphorylation of ErbB-2
Zhou, W., & Carpenter, G. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204517 · Cited by 27
Baselga, J. M., & Tabernero, J. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8900 · Cited by 23
The “Other” Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs
Gianni, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7404 · Cited by 21
Banna, G. L., Aversa, S. M. L., Crivellari, G., Ghiotto, C., Chiarion‐Sileni, V., & Monfardini, S. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603114 · Cited by 3
Cited by
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Metadata
- Authors
- Spector, N. L., & Blackwell, K. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-12-01
- Volume
- 27
- Issue
- 34
- Pages
- 5838-5847
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2089071484
- Cited by
- 497
- References
- 97
- FWCI
- 20.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.